Farmas USA

Advanced Cell Tech's debtors want their money http://seekingalpha.com/currents/post/1723473?source=ansh $ACTC
Jooo pero no se decia qué pasará al NASDAQ

CMXI

Por resumir: Results from RECOVER-Stroke Phase 2 Trial Show No Significant Clinical Benefit

http://seekingalpha.com/pr/9801433-cytomedix-announces-results-of-recover-stroke-phase-2-study-provides-update-on-r-and-d-reorganization-and-ongoing-launch-initiatives-for-autologel-tm

Pues eso, que otras vendrán que me hagan llorar. A ver que descalabro hay mañana. :_(

FOLD

Earnings. http://seekingalpha.com/news/1723643-amicus-therapeutics-misses-by-0_01-beats-on-revenues

ACTC

He llegado a poner orden en 0'0594 y no ha entrado por los pelos. A ver como reacciona mañana, en principio el default ya se sabía y como dijo Anaramos hay un plan para solventarlo a base de vender patentes. La cuestión es si los acreedores se tragan dicho plan.

ACTC

Nonono. Esa noticia dice lo contrario, que se ha pagado esa deuda, pero que se hizo en un momento a posteriori por cuestiones de leyes bursátiles X, pero que la parte deudora tuvo que notificarlo; es decir, que no deben nada. Edito: ya dije en su momento que no era posible, que ese pago constaba en la contabilidad. Lo que pasa es que ya sabemos lo que aprovechan algunos para cargar.

On April 29, 2014, Advanced Cell Technology, Inc. (the “Company”) received notice (the “Acceleration Notice”) from each of CAMOFI Master LDC (“CAMOFI”) and CAMHZN Master LDC (“CAMHZN” and together with CAMOFI, the “Holders”) of the Holders’ declaration that the aggregate principal amount remaining under the Amortizing Senior Secured Convertible Notes due June 30, 2015 issued by the Company and held by each of CAMOFI and CAMHZN (collectively, the “Notes”), subject to adjustment as set forth therein, together with any other amounts owed under the Notes (collectively, the “Owed Amount”), were immediately due and payable in accordance with their terms. The Acceleration Notice followed the delivery of a notice (the “Default Notice”) from the Holders to the Company on April 15, 2014 stating that, due to the Company’s failure to deliver shares of common stock issuable to the Holders within three days of a conversion event, an “Event of Default” under the Notes had occurred and the Holders were reserving all rights held by them arising from such Event of Default. At the time of the conversion event, the Company determined not to deliver the shares to the Holders in order to comply with applicable securities laws. The Company later delivered the shares to the Holders in compliance with applicable securities laws, prior to the delivery of the Default Notice. The right of the Holders to make a declaration of acceleration under the Notes, as well as the delivery to the Company of the Default Notice, was previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 21, 2014.

ACTC

O sea que ya no la pillo a menos de esos 0'06

A saber... 0,06 también es buen precio.

http://boardvote.com/symbol/AZN/communique/635393

FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
WILMINGTON, Del., May 6, 2014 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced the US Food and Drug Administration (FDA) approved EPANOVA® (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).